We are in the middle of radiopharmaceuticals shortages -both Molybdenum and Iodine 131. The BNMS has been working with DHSC, UKRG and industry to mitigate the supply issues. Molybdenum supply is already improving. I would like to thank Jilly Croasdale for leading the vital work on this for the BNMS. I would also like to congratulate Jilly on becoming BNMS President-elect. Jilly is very experienced in all matters nuclear medicine from her work both as BNMS Treasurer and as a radiopharmacist.  I know Jilly will be a great leader of our community and we are very fortunate that she has found the time to take on this important role. There are statements from the BNMS on our website front page around the current radiopharmaceutical supply situation and suggested mitigations that you my wish to read.
 
Gary Cook from St Thomas’ PET-CT centre has kindly agreed to lead the BNMS task and finish group on defining standards in PET-CT service provision. This is a really important project which we hope will inform the procurement of PET-CT services in the future whether this is national or local. We are keen to make sure our patients get the he quality of service they deserve and that vital aspects of the whole service, such as physics support, are not diminished.
 
We have had a very large number of abstract submissions for spring meeting in Glasgow which is fantastic to see. The meeting is really shaping up to be a memorable event form both a learning and socialising perspective. I urge you to register for the meeting if you have not done so already and I looking forward to seeing you all there.
 
I am speaking on the future if theranostics at the winter SNMMI meeting next week which now sadly I will be attending from my house rather that being in Florida! As a result of giving the talk I have done much reading around theranostics and I really can see this to be a big part of what we will do in the future as a community. This will be a pillar of personalised medicine particularly in cancer care. We hope that NICE will approve Lu177-PSMA for NHS use in the autumn which will potentially be the vanguard for mainstream theranostics in the UK. This is a really exciting time to be working in Nuclear Medicine!

Prof Richard Graham

BNMS President